Bitcoin halving
What does that mean?
$2.78T
Total marketcap
$143.68B
Total volume
BTC 49.85%     ETH 15.42%
Dominance

ADC Therapeutics SA ADCT Stock

4.2 USD {{ price }} -3.448278% {{change_pct}}%
Exchange
NYSE
Market Cap
346.62M USD
LOW - HIGH [24H]
4.07 - 4.43 USD
VOLUME [24H]
235.12K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-2.94 USD

ADC Therapeutics SA Price Chart

ADC Therapeutics SA ADCT Financial and Trading Overview

ADC Therapeutics SA stock price 4.2 USD
Previous Close 2.29 USD
Open 2.27 USD
Bid 2.32 USD x 900
Ask 2.61 USD x 1400
Day's Range 2.27 - 2.36 USD
52 Week Range 1.85 - 10.88 USD
Volume 157.23K USD
Avg. Volume 511.53K USD
Market Cap 186.28M USD
Beta (5Y Monthly) 1.082883
PE Ratio (TTM) N/A
EPS (TTM) -2.94 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 10.67 USD

ADCT Valuation Measures

Enterprise Value 220.45M USD
Trailing P/E N/A
Forward P/E -0.9871795
PEG Ratio (5 yr expected) 0.27
Price/Sales (ttm) 1.0212835
Price/Book (mrq) 4.9570813
Enterprise Value/Revenue 1.209
Enterprise Value/EBITDA -1.651

Trading Information

ADC Therapeutics SA Stock Price History

Beta (5Y Monthly) 1.082883
52-Week Change -63.62%
S&P500 52-Week Change 20.43%
52 Week High 10.88 USD
52 Week Low 1.85 USD
50-Day Moving Average 2.28 USD
200-Day Moving Average 3.64 USD

ADCT Share Statistics

Avg. Volume (3 month) 511.53K USD
Avg. Daily Volume (10-Days) 259.83K USD
Shares Outstanding 80.64M
Float 50.5M
Short Ratio 14.57
% Held by Insiders 32.60%
% Held by Institutions 64.31%
Shares Short 6.07M
Short % of Float 13.55%
Short % of Shares Outstanding 7.53%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -108.86%
Operating Margin (ttm) -73.79%
Gross Margin 9.32%
EBITDA Margin -73.20%

Management Effectiveness

Return on Assets (ttm) -16.032%
Return on Equity (ttm) -198.21%

Income Statement

Revenue (ttm) 182.4M USD
Revenue Per Share (ttm) 2.31 USD
Quarterly Revenue Growth (yoy) -59.19%
Gross Profit (ttm) 35.1M USD
EBITDA -133529000 USD
Net Income Avi to Common (ttm) -198564992 USD
Diluted EPS (ttm) -2.27
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 310.55M USD
Total Cash Per Share (mrq) 3.84 USD
Total Debt (mrq) 345.96M USD
Total Debt/Equity (mrq) 918.02 USD
Current Ratio (mrq) 4.686
Book Value Per Share (mrq) 0.466

Cash Flow Statement

Operating Cash Flow (ttm) -117683000 USD
Levered Free Cash Flow (ttm) -70353128 USD

Profile of ADC Therapeutics SA

Country United States
State N/A
City Epalinges
Address Biopole
ZIP 1066
Phone 41 21 653 02 00
Website https://www.adctherapeutics.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 317

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; and LOTIS-7, a Phase Ib clinical trial for treatment of relapsed or refractory B-cell lineage non-hodgkin lymphoma (B-NHL). The company is also developing camidanlumab tesirine, an ADC composed of a monoclonal antibody that binds to CD25 conjugated to a PBD–dimer toxin, as well as in Phase II clinical trial in relapsed or refractory hodgkin lymphoma. In addition, it develops ADCT-602, which is in Phase I/II clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 that are in Phase Ia clinical trial for treatment of various solid tumors and hematological malignancies; and ADCT-212, a second-generation PBD-based ADC targeting prostate-specific membrane antigen (PSMA), including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Q&A For ADC Therapeutics SA Stock

What is a current ADCT stock price?

ADC Therapeutics SA ADCT stock price today per share is 4.2 USD.

How to purchase ADC Therapeutics SA stock?

You can buy ADCT shares on the NYSE exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for ADC Therapeutics SA?

The stock symbol or ticker of ADC Therapeutics SA is ADCT.

Which industry does the ADC Therapeutics SA company belong to?

The ADC Therapeutics SA industry is Biotechnology.

How many shares does ADC Therapeutics SA have in circulation?

The max supply of ADC Therapeutics SA shares is 82.53M.

What is ADC Therapeutics SA Price to Earnings Ratio (PE Ratio)?

ADC Therapeutics SA PE Ratio is now.

What was ADC Therapeutics SA earnings per share over the trailing 12 months (TTM)?

ADC Therapeutics SA EPS is -2.94 USD over the trailing 12 months.

Which sector does the ADC Therapeutics SA company belong to?

The ADC Therapeutics SA sector is Healthcare.

ADC Therapeutics SA ADCT included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NYSE COMPOSITE (DJ) NYA 18255.24 USD
+1.09